|View printer-friendly version|
Array BioPharma Provides Clinical Update On ARRY-502 For Asthma At Scientific Meeting
ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in the U.S. ARRY-502 met the primary endpoint in the trial, showing improved pre-bronchodilator Forced Expiratory Volume in one second (FEV1), a measure of lung function, by 3.9% versus placebo, achieving statistical significance (p=0.02). FEV1 responses for the total cohort were statistically significant on a week by week basis. A predefined endpoint using the median baseline value of FENO (fractional exhaled nitric oxide), a Th2 associated biomarker, was also evaluated. FENO measurement is an office-based, noninvasive method for evaluating pulmonary inflammation. Patients with elevated baseline FENO demonstrated enhanced activity with a median FEV1 improvement of 6.8% relative to placebo at week 4 (p=0.008). This is the first published report demonstrating that CRTh2 antagonism provides meaningful clinical benefit specifically in patients with high FENO.
Secondary efficacy endpoints also achieved statistical significance, including:
- Reduced short-acting beta agonist (SABA) use [approximately 6 puffs per week difference versus placebo (p<0.001)]
- Asthma control as measured by the Asthma Control Questionnaire (ACQ) (p<0.001)
- Forced Vital Capacity (FVC) improvement (p=0.006)
- Improvement in Rhinasthma and Asthma Quality of Life questionnaires (AQLQ) (p=0.007 and p=0.012, respectively)
Overall, ARRY-502 was well tolerated, with fewer adverse events in the ARRY-502 group as compared to the placebo group, including fewer asthma exacerbations (ARRY-502, n=4; placebo, n=9). There were no treatment-emergent serious adverse events in patients receiving ARRY-502 and all treatment-related adverse events were mild or moderate in severity. In addition, there were no significant changes observed in the safety signals QTc, hematology or vital signs in patients treated with ARRY-502. A total of 15 out of 184 patients discontinued the study early with fewer discontinuations occurring on the ARRY-502 arm (ARRY-502, n=4; placebo, n=11). Six of these discontinuations were due to asthma exacerbations (ARRY-502, n=1; placebo, n=5).
"From these data, ARRY-502 shows robust activity in patients with Th2-driven mild-to-moderate asthma," said
Ron Squarer, Chief Executive Officer of Array, noted, "With many asthma patients poorly controlled on currently available therapies, especially among severe asthmatics, an oral drug targeting a novel anti-inflammatory mechanism may present an important new option for millions of patients. We are seeking an appropriate partner to develop ARRY-502 to its full potential."
About ARRY-502 and CRTh2
ARRY-502 is an oral, potent and highly selective CRTh2 antagonist designed to treat patients with allergic asthma. The CRTh2 receptor is expressed on Th2 T cells, basophils and eosinophils, and its ligand, prostaglandin D2 (PGD2), is released by mast cells. The results of this study demonstrate that the PGD2/CRTh2 axis plays a key role in the migration and activation of inflammatory cells leading to many symptoms of asthma including coughing, difficulty breathing and exacerbations. Because current asthma therapies do not fully target the Th2 pathway, antagonism of CRTh2 represents an exciting new approach to enhance disease control.
Based on its mechanism of action, ARRY-502 may provide the most patient benefit in a Th2 gene signature-enriched population. Several baseline Th2-related biomarkers were evaluated in the Phase 2 study. The Th2 gene signature, which is present in about half of the asthma population, spans mild, moderate and severe disease and suggests broad applicability for ARRY-502 in these patients as well as in other Th2-driven diseases like allergic rhinitis and atopic dermatitis.
It is estimated that approximately 25 million people in
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the potential for the results of ongoing clinical trials to support further development, regulatory approval or the marketing success of ARRY-502, and future plans to progress, develop and partner ARRY-502. These statements involve significant risks and uncertainties, including those discussed in the most recent annual report filed on form 10-K, quarterly reports filed on Form 10-Q, and other reports filed by Array with the